GlassScriptPhysician profile
Dan J Gzesh
NPI 1417984923
$11,205.64
in general payments reported to CMS, 2019-2025
55 companies · $2,476 in 2025
The $2,476 reported for 2025 was more than what 76% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,261 · 2020: $824 · 2021: $595 · 2022: $150 · 2023: $383 · 2024: $5,516 · 2025: $2,476.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,815 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $1,715 · Food and Beverage: $1,418 · Travel and Lodging: $426.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,815.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $1,715.00 |
| Food and Beverage | $1,418.43 |
| Travel and Lodging | $425.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $7,230.57 | 2019-2025 | |
| Abbvie INC. | $487.16 | 2021-2025 | |
| Supernus Pharmaceuticals, INC. | $383.69 | 2019-2020 | |
| Biogen, INC. | $329.47 | 2019-2025 | Aduhelm, Leqembi |
| Argenx US, INC. | $205.60 | 2024-2025 | Vyvgart Hytrulo, Vyvgart |
| Alexion Pharmaceuticals, INC. | $200.69 | 2019-2024 | Ultomiris |
| Csl Behring | $191.70 | 2019-2025 | Hizentra |
| Akcea Therapeutics, INC. | $188.45 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $143.94 | 2021 | |
| Allergan, INC. | $143.85 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $120.95 | 2019 | |
| Genzyme Corporation | $99.29 | 2019-2020 | |
| Upsher-Smith Laboratories LLC | $82.29 | 2019-2020 | |
| Lilly USA, LLC | $78.34 | 2019-2024 | Kisunla |
| Ucb, INC. | $77.55 | 2020-2025 | Nayzilam |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dan Gzesh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.